A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis

Drugs and Aging

Volumn 23, Issue 3, 2006, Pages 263-270

  Signorelli, Salvatore Santo ^a   Fatuzzo, Pasquale ^a   Rapisarda, Francesco ^a   Neri, Sergio ^a   Ferrante, Margherita ^b   Conti, Gea Oliveri ^b   Fallico, Roberto ^b   Di Pino, Luigi ^a   Pennisi, Giuseppe ^a   Celotta, Gabriella ^a   Massimiliano, Anzaldi ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; MALONALDEHYDE; NITRATE; NITRITE; PLACEBO; PROPIONYLCARNITINE;

ABSENCE OF SIDE EFFECTS; AGED; ANALYTICAL PARAMETERS; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEMODIALYSIS; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OXIDATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALDEHYDES; CARNITINE; DOUBLE-BLIND METHOD; HUMANS; MALONDIALDEHYDE; MIDDLE AGED; NITRATES; NITRITES; OXYGEN; PERIPHERAL VASCULAR DISEASES; PLACEBOS; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 33645790536     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623030-00008     Document Type: Article

References (35)

1. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002; (80): 35-8
2. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16 (2): 85-94
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (4 Suppl. 1): S117-31
4. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10 (7): 1606-15
5. Coresh J, Longenecker JC, Miller 3rd ER, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl.): S24-30
6. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58 (1): 353-62
7. O'Hare AM, Glidden DV, Fox CS, et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004; 109 (3): 320-3
8. Lamar Welch VL, Casper M, Greenlund K, et al. Prevalence of lower extremity arterial disease defined by the ankle-brachial index among American Indians: the Inter-Tribal Heart Project. Ethn Dis 2002; 12 (1): S1-63-7
9. Violi F, Loffredo L, Marcoccia A. Antioxidants in peripheral arterial disease. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4 (3): 289-94
10. Ikizler TA. Role of nutrition for cardiovascular risk reduction in chronic kidney disease patients. Adv Chronic Kidney Dis 2004; 11 (2): 162-71
11. Sato M, Matsumoto Y, Morita H, et al. Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease. Clin Nephrol 2003; 60 (1): 28-34
12. Violi F, Loffredo L, Mancini A, et al. Antioxidants in peripheral arterial disease. Curr Drug Targets 2003; 4 (8): 651-5
13. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27 (5 Pt 1): 535-42
14. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003; 42 (11): 941-67
15. Brass EP, Hoppel CL. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J 1980; 190 (3): 495-504
16. Cittanti C, Colamussi P, Giganti M, et al. Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. Eur J Nucl Med 1997; 24 (7): 762-6
17. Brevetti G, Angelini C, Rosa M, et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84 (4): 1490-5
18. Signorelli SS, Malaponte G, Di Pino L, et al. Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration. Pharmacol Res 2001; 44 (4): 305-9
19. Evans AM, Faull RJ, Nation RL, et al. Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 2004; 66 (4): 1527-34
20. Steiber AL, Weatherspoon LJ, Spry L, et al. Serum carnitine concentrations correlated to clinical outcome parameters in chronic hemodialysis patients. Clin Nutr 2004; 23 (1): 27-34
21. Miller B, Ahmad S. A review of the impact of L-carnitine therapy on patient functionality in maintenance hemodialysis. Am J Kidney Dis 2003; 41 (4 Suppl. 4): S44-8
22. Hurot JM, Cucherat M, Haugh M, et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13 (3): 708-14
23. Brass EP, Adler S, Sietsema KE, et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001; 37 (5): 1018-28
24. Leriche R. Physiologie pathologique et traitement chirurgical des maladies artérielles de la vaso-motricité. Premier édition. Paris: Masson et Cie, 1945
25. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 2000; 50 (4-5): 315-21
26. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003; 42 (4): 318-43
27. Nims R, Derbyshire J, Saavedra J, et al. Colorimetric methods for the determination of nitric oxide concentration in neutral aqueous solutions. Methods 1995; 7: 48-54
28. Davis EJ, Spydevold O, Bremer J. Pyruvate carboxylase and propionyl-CoA carboxylase as anaplerotic enzymes in skeletal muscle mitochondria. Eur J Biochem 1980; 110 (1): 255-62
29. Hiatt WR, Wolfel EE, Regensteiner JG, et al. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73 (1): 346-53
30. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77 (4): 767-73
31. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356 (9237): 1213-8
32. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163 (8): 884-92
33. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326 (6): 381-6
34. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41 (8): 1364-72
35. Signorelli S, Neri S, Di Pino L, et al. Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. Diabetes Res Clin Pract. In press